lxrx fda approval date:Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
2023年5月30日—Thenewdrugapplication(NDA)forInpefawasacceptedbythefoodanddrugadministration(FDA)inJune2022.LexiconexpectstomakeInpefa ...。其他文章還包含有:「LexiconAnnouncesFDAAcceptanceofNewDrugApplication」、「LexiconAnnouncesFDAApprovalofINPEFA™(sotagliflozin)」、「LexiconPharma」、「LexiconPharmaceuticalsInc.,LXRX」、「LexiconPharmaceuticalsReportsSecondQuarter2023...」、「Lexicon's(L...
查看更多 離開網站Lexicon Announces FDA Acceptance of New Drug Application
https://www.globenewswire.com
The FDA assigned a standard review for the NDA filing with a Prescription Drug User Fee Act (PDUFA) target action date in May 2023.
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin)
https://www.globenewswire.com
THE WOODLANDS, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug ...
Lexicon Pharma
https://seekingalpha.com
Lexicon's sotagliflozin, armed with strong data, will have a PDUFA in May 2023. Click to read more as I think this could boost up LXRX stock ...
Lexicon Pharmaceuticals Inc., LXRX
https://www.rttnews.com
Outcome Date, 05/26/2023 ; Outcome, FDA approved Sotagliflozin, under brand name INPEFA, for treatment of Heart Failure on May 26, 2023 ; Drug ...
Lexicon Pharmaceuticals Reports Second Quarter 2023 ...
https://finance.yahoo.com
On May 26, Lexicon announced that the U.S. Food and Drug Administration (FDA) approved INPEFA (sotagliflozin), a once-daily oral tablet to ...
Lexicon's (LXRX) Heart Failure Drug Inpefa ...
https://finance.yahoo.com
Lexicon's LXRX shares were up almost 18% on May 26, after market hours. The rise was due to the FDA approval of a broad label for Inpefa ...
LXRX stock on watch on FDA review of heart failure therapy ...
https://seekingalpha.com
Lexicon heart failure therapy undergoes FDA review again. Jul. 27, 2022 8:23 AM ETLexicon Pharmaceuticals, Inc. (LXRX)By: ...
May 27 PDUFA Date For Heart Failure Drug Looks Crucial
https://seekingalpha.com
Lexicon ought to find out whether its heart failure candidate sotagliflozin will be approved on May 27. Read why LXRX stock is a hold.
U.S. FDA approves Lexicon Pharma's drug for heart failure
https://www.reuters.com
May 26 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's (LXRX.O) drug for a broad ...